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ABSTRACT 
Aims: The Glu167Lys (E167K) variant in TM6SF2 was recently shown to influence liver fat 
(LFAT) content. We aimed at studying how the variant influences the circulating triacylglycerol 
(TAG) signature and whether it influences hepatic or adipose tissue insulin sensitivity.  
Methods: We genotyped 300 Finnish subjects for E167K (rs58542926) in TM6SF2 and for I148M 
(rs738409) in PNPLA3 in whom LFAT was measured using 1H-MRS and circulating lipids by 
UPLC-MS. We compared plasma lipidome between E167K carriers (TM6SF2EK/KK) and non-
carriers (TM6SF2EE), and between three groups of NAFLD: i) carriers of E167K but not the I148M 
variant in PNPLA3 (‘TM6SF2 NAFLD’), ii) carriers of the I148M but not the E167K variant 
(‘PNPLA3 NAFLD’) and iii) non-carriers of either risk allele (‘Non-risk NAFLD’). Hepatic and 
adipose tissue insulin sensitivities were measured using the euglycemic hyperinsulinemic clamp 
technique combined with infusion of [3-3H]glucose in 111 subjects.  
Results: LFAT content was 34% higher in TM6SF2EK/KK (13.07±1.57%) than TM6SF2EE 
(9.77±0.58%, p = 0.013). Insulin sensitivities of glucose production and lipolysis were significantly 
higher at any given LFAT in the TM6SF2EK/KK than in the TM6SF2EE group. Comparison of three 
NAFLD groups with similar LFATs showed that both the ‘TM6SF2 NAFLD’ and ‘PNPLA3 
NAFLD’ had significantly lower triglyceride levels and were characterized by lower levels of most 
common TAGs compared to the ‘Non-risk NAFLD’ group.  
Conclusions: We conclude that the E167K variant in TM6SF2 is associated with distinct subtype of 
NAFLD characterized by preserved insulin sensitivity of lipolysis and hepatic glucose production 
and lack of hypertriglyceridemia despite clearly increased LFAT content.  
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Introduction  
 
Genetic factors contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). In 
2008, an allele in PNPLA3 (rs738409[G], encoding I148M) was found to be highly significantly 
associated with NAFLD in three different ethnic group [1]. This finding has subsequently been 
robustly replicated in over 50 studies including eight genome wide association scans [2]. Recently, 
genetic variation in TM6SF2 at rs58542926 was shown to confer susceptibility to NAFLD 
independent of genetic variation at rs738409 in PNPLA3 in the Dallas Heart Study [3]. The 
TM6SF2 variant associated with NAFLD is a guanine to adenine substitution, which replaces 
glutamate at residue 167 with lysine (E167K). The frequency of the variant allele was higher in 
individuals of European (7.2%, n=882) than of other ancestry groups. TM6SF2 variant allele 
carriers had significantly lower serum TAG concentrations than non-carriers in some but not all 
ethnic groups. The latter included European Americans [3]. Expression of the variant allele in 
cultured hepatocytes decreased production of the E167K TM6SF2 protein. Short hairpin RNA 
knockdown of TM6SF2 in mice increased triglyceride content three-fold and decreased VLDL 
secretion [3].  
 
We have previously shown that rs738409 in PNPLA3 is associated with a distinct circulating TAG 
signature compared to obesity-associated NAFLD [4]. In the present study, we examined how the 
variant influences the circulating TAG signature as measured by UPLC-MS and whether it 
influences directly measured hepatic or adipose tissue insulin sensitivity. We also compared the 
plasma lipidome between three groups with NAFLD: those carrying only the E167K variant in 
TM6SF2 but not the I148M allele in PNPLA3 (‘TM6SF2 NAFLD’), another carrying only the 
I148M risk allele in PNPLA3 (‘PNPLA3 NAFLD’) and those carrying neither of these risk alleles 
(‘Non-risk NAFLD’). 
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Materials and methods 
Subjects and study design 
Metabolic studies were conducted at the University Central Hospital of Helsinki, Finland. The 
subjects (n=300) were recruited using the following criteria: (a) age 18 to 75 years; (b) no known 
acute or chronic disease except for obesity or type 2 diabetes based on medical history, physical 
examination and standard laboratory tests (blood counts, serum creatinine, thyroid-stimulating 
hormone, electrolyte concentrations) and electrocardiogram; (c) alcohol consumption less than 20 g 
per day. Elevated liver enzymes (serum alanine aminotransferase [ALT], and aspartate 
aminotransferase [AST]) were not exclusion criteria. However, subjects with clinical or 
biochemical evidence of hepatitis B or C, autoimmune hepatitis, or with clinical signs or symptoms 
of inborn errors of metabolism or a history of use of toxins or drugs associated with liver steatosis 
were excluded. Eighty-two subjects had type 2 diabetes. Patients were excluded if they used 
thiazolidinediones or were pregnant. Lipidomics data on a larger study group have been previously 
reported [4]. The present study included subjects from whom DNA could be obtained for 
genotyping of PNPLA3 at rs738409 and TM6SF2 at rs58542926. The study protocol was approved 
by the ethics committee of the Helsinki University Central Hospital. Each participant signed an 
informed consent form for participation in the metabolic study and another permitting blood 
sampling and analysis of polymorphisms in genes related to LFAT content. 
 
In eligible subjects, a blood sample was taken after an overnight fast for lipidomic analyses (vide 
infra) and for measurement of glucose, insulin, total TAGs, total and HDL cholesterol, AST, ALT 
and GGT concentrations. A blood sample was also obtained at this visit or by inviting the subjects 
to a separate visit, for isolation of DNA and genotyping. In each subject, LFAT content was 
measured (vide infra). Direct measurement of hepatic and adipose tissue insulin sensitivity using 6-
hour infusions of [3-3H]glucose and glucose and insulin were performed in 111 of the subjects (vide 
infra). 
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Lipidomic analysis with UPLC-MS 
An unthawed plasma sample was extracted for lipidomic analysis (vide infra). An established 
platform based on Acquity Ultra Performance LCTM coupled to quadruple time-of-flight mass 
spectrometry (UPLC-MS) was used to analyze the plasma samples [5].  
 
An aliquot (10 µL) of the plasma sample was diluted with 10 µL of 0.15 M (0.9%) sodium chloride 
and 10 µL of internal standard mixture 1A was added. This mixture contained PC(17:0/0:0), 
PC(17:0/17:0), PE(17:0/17:0), PG(17:0/17:0), Cer(d18:1/17:0), PS(17:0/17:0) and PA(17:0/17:0) 
(Avanti Polar Lipids, Inc., Alabaster, AL) as well as mono-triglycerides (17:0/0:0/0:0), di-
triglycerides(17:0/17:0/0:0) and TAG(17:0/17:0/17:0).  The lipids were extracted using a mixture of 
HPLC-grade chloroform and methanol (2:1; 100 µL). The lower phase (60 µL) was collected and 
10 µL of an internal standard mixture containing labeled PC (16:1/0:0-D3), PC(16:1/16:1-D6) and 
TAG(16:0/16:0/16:0-13C3) was added.   
 
The extracts were analyzed on a Waters Q-Tof Premier mass spectrometer combined with an 
Acquity Ultra Performance LCTM. The column (at 50 °C) was an Acquity UPLCTM BEH C18 2.1 × 
100 mm with 1.7 µm particles. The solvent system included A. ultrapure water (1% 1 M NH4Ac, 
0.1% HCOOH) and B. LC/MS grade acetonitrile/isopropanol (1:1, 1% 1M NH4Ac, 0.1% HCOOH). 
The gradient started from 65% A / 35% B, reached 80% B in 2 min, 100% B in 7 min and remained 
there for 7 min. The flow rate was 0.400 ml/min and the injected amount was 2.0 µl (Acquity 
Sample Organizer, at 10 °C). Reserpine was used as the lock spray reference compound. Lipid 
profiling was carried out using electrospray ionization in positive ion mode and data were collected 
at a mass range of m/z 300-1200 with scan duration of 0.2 sec.  
 
The data processing including alignment of peaks, peak integration, normalization and 
identification was done by using MZmine 2 software [6] and the lipid identification was based on 
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an internal spectral library or on de novo identification using tandem MS [5]. Data were normalized 
by using one or more internal standards representative of each class of lipid present in the samples: 
the intensity of each identified lipid was normalized by dividing it with the intensity of its 
corresponding standard and multiplying it by the concentration of the standard. All monoacyl lipids 
except cholesterol esters, such as monoacylglycerols and monoacylglycerophospholipids, were 
normalized with PC(17:0/0:0), all diacyl lipids except ethanolamine phospholipids were normalized 
with PC(17:0/17:0), all ceramides with Cer(d18:1/17:0), all diacyl ethanolamine phospholipids with 
PE(17:0/17:0), and TAG and cholesterol esters with TAG(17:0/17:0/17:0). Other (unidentified) 
molecular species were normalized with PC(17:0/0:0) for retention times < 300 s, PC(17:0/17:0) for 
a retention time between 300 s and 410 s, and TAG(17:0/17:0/17:0) for longer retention times. For 
further identification of unknown lipids, please see supplementary material for detail. 
  
LFAT content  
LFAT content was measured by proton magnetic resonance spectroscopy (1H-MRS) as previously 
described and validated against histologic measurement of LFAT [7]. In a few subjects (n=36), 
LFAT was measured using a liver biopsy. The fat content of the liver biopsy specimens (the 
percentage of hepatocytes with macrovesicular steatosis) was determined using hematoxylin-eosin 
staining and converted to 1H-MRS LFAT percentage units, as previously described [7]. NAFLD 
was defined as LFAT ≥55.6 mg triglyceride per gram of liver tissue or ≥5.56% of liver tissue 
weight [8]. 
 
Genotyping  
Genomic DNA was extracted from whole blood. Genotyping was performed using Taqman PCR 
method (Applied Biosystems, Foster City, CA, USA) according to manufacturer’s instructions. ABI 
Prism Sequence Detection Systems ABI 7900HT (Applied Systems) was used for post-PCR allelic 
discrimination by measuring allele-specific fluorescence. The success rate for genotyping was 
 10 
>95%. Genotyping was performed twice in two independent analyses and the concordance rate was 
100%. The genotypes were in Hardy-Weinberg equilibrium. 
 
Hepatic and adipose tissue insulin sensitivity 
Insulin sensitivities of hepatic glucose production and peripheral glucose utilization as well as of 
the antilipolytic effect of insulin were assessed by the euglycemic hyperinsulinemic clamp 
technique combined with infusion of [3-3H]glucose as previously described [9]. Because hepatic 
glucose production is more sensitive to suppression by insulin than stimulation of muscle glucose 
uptake, we used a low insulin infusion rate (0.3 mU/kg·min) to accurately quantify interindividual 
variation in hepatic insulin sensitivity. These measurements were available from 111 subjects. The 
rate of glucose endogenous production and the rate of glucose disposal were calculated using 
Steele’s non-steady-state equations. Since insulin clearance is altered by a fatty liver [7], hepatic 
insulin sensitivity was calculated by dividing the % suppression of hepatic glucose production by 
the mean S-insulin concentration (mU/l). Adipose tissue insulin sensitivity was calculated by 
dividing the % suppression of S-free fatty acids (S-FFA) by insulin by the mean S-insulin 
concentration (mU/l) [9].  
 
Other analytical procedures and measurements 
Body weight was recorded to the nearest 0.1 kg using a calibrated weighting scale with subjects 
standing barefoot and wearing light indoor clothing. Waist circumference was measured midway 
between spina iliaca superior and the lower rib margin. Body height was recorded to the nearest 0.5 
centimeter. Blood pressure, fP-glucose, fS-insulin, fS-LDL cholesterol, total serum cholesterol, fS-
HDL cholesterol, fS-TAG, AST, ALT, ALP and GGT concentrations were measured as previously 
described [10]. Homeostasis model assessment of insulin resistance (HOMA-IR) was estimated by 
using formula: HOMA-IR = fS-insulin (mU/l) × fP-glucose (mmol/l)/22.5 [11]. ‘Non-alcoholic 
steatohepatitis (NASH) score’ was calculated as previously reported [12]. 
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Statistical analyses 
All data were tested for normality using the Kolmogorov-Smirnov test. Normally distributed data 
are shown as means ± SEM and non-normally distributed data are shown as medians followed by 
the 25th and 75th quartiles. The unpaired t-test and the Mann-Whitney test were used to compare 
normally and non-normally distributed data, respectively. One-way analysis of variance (ANOVA) 
was used to compare three NAFLD groups. The least square difference test was used for post hoc 
analyses. Non-normally distributed data were used after log10 transformation. Analysis of 
covariance (ANCOVA) was used to compare slopes and intercepts of regression lines of the 
associations between insulin sensitivities and LFAT content in different genotype carriers. The 
statistical analyses were performed by using R (http://www.r-project.org/) and STATA version 13.1 
for Mac (StataCorp LP, College Station, TX). Figures were produced by R and GraphPad Prism 6 
for Mac (GraphPad Software Inc., San Diego, CA).  A two-sided p value of less than 0.05 was 
considered statistically significant. 
 
Assessment of abundances of TAG species 
Mean values and standard errors of abundances of plasma TAG molecular species were calculated. 
After log2 transformation, the mean values of TAG abundances were compared between TM6SF2 
variant and wide-type by using student’s t-tests. Multiple comparisons were corrected by using 
Benjamini-Hochberg's method [13]. The comparisons of abundances of TAG molecules were 
illustrated by heatmaps, which show fatty acid chain lengths and number of double bonds. Log2 
transformed ratios of the TAG values of variant divided by non-variant allele carriers were 
visualized by each cell in the heatmap. R Package, metadar (http://code.google.com/p/metadar) was 
used for data analysis. 
  
Analysis of lipidomics data 
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Groups of lipids with similar profiles were identified by using Bayesian model-based clustering as 
previously described [4]. 
 
Results 
Comparison of TM6SF2 gene variant carriers (TM6SF2EK/KK) to non-carriers (TM6SF2EE) 
The allele frequency of E167K was 7.2% with 0.7% being homozygous and 13% heterozygous for 
the K-allele. For comparison, the allele frequency of the I148M variant in PNPLA3 was 27.8% with 
6.0% being homozygous and 43.7% heterozygous. Age, gender, body weight, BMI, fasting plasma 
glucose concentrations and PNPLA3 genotypes were similar between the TM6SF2EK/KK and 
TM6SF2EE groups (Table 1). Carriers of the TM6SF2 gene variant (TM6SF2EK/KK) had 34% higher 
mean LFAT (mean±SE: 13.07±1.57% vs 9.77±0.58%, p-value = 0.013. Fig. 1) or 65% higher 
median LFAT  [median (25th - 75th percentiles): 11.2 (4.4-19.7)% vs 6.8 (2.1-15.6)%, p-value = 
0.03)] than those lacking the variant (TM6SF2EE). Serum TAG, LDL and HDL cholesterol and liver 
enzyme concentrations were comparable between the groups (Table 1).  
 
We also compared patients with type 2 diabetes who were TM6SF2 variant carriers (TM6SF2EK/KK) 
to non-carriers (TM6SF2EE). The TM6SF2EK/KK group (n=10) compared to the TM6SF2EE  group 
(n=72) had significantly higher LFAT content (mean±SE: 19.4±3.0 vs. 13.4±1.1%, p = 0.02) and 
were almost significantly less obese (32.0±1.7 vs 36.3±1.0 kg/m2, p = 0.059). The groups were 
comparable with respect to age (54±3 vs. 52±1 yrs), gender (80% vs. 60% men, p = 0.37), fasting 
serum TAGs (2.1±0.3 vs. 2.2±0.2 mmol/l), insulin (14.1±1.7 vs. 16.4±1.3 mU/l), HOMA-IR 
(6.7±1.0 vs. 6.0±0.5) and PNPLA3 genotype.   
 
Serum lipidome in TM6SF2EK/KK vs. TM6SF2EE 
Using the UPLC-MS based analytical platform, a total of 411 molecular lipids were measured and 
157 identified. Total fS-TAGs measured enzymatically in the clinical laboratory (1.81±0.077 
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mmol/l, n=300) were highly correlated with the sum of plasma TAGs identified by UPLC-MS 
(0.83±0.026 mmol/l, r=0.88, p < 0.001). The lipidomic platform data were decomposed into 9 lipid 
clusters (LCs), which to a large extent adhered to different lipid functional or structural groups 
(Supplementary Table 1). TAGs were particularly enriched in LC1 and LC6. LC1 was slightly 
lower (p=0.07) in TM6SF2EK/KK as compared to the TM6SF2EE group. Plasma TAG composition 
did not differ between the groups (Fig. 1).  
 
Insulin sensitivity 
ANCOVA showed that there was no significant interaction between TM6SF2 genotype and insulin 
sensitivity of hepatic glucose production (p = 0.87) or lipolysis (p = 0.31). However, for any given 
LFAT content, as judged from significant differences in the intercepts between the regression lines, 
hepatic insulin sensitivity of glucose production (p = 0.002) and adipose tissue lipolysis (p = 0.012) 
were significantly higher in the TM6SF2EK/KK than the TM6SF2EE group (Fig. 2).  
 
Comparison of NAFLD groups 
Table 2 shows the subjects, who had NAFLD (n=154) of all 300 subjects. The ‘TM6SF2 NAFLD’, 
‘PNPLA3 NAFLD’, and ‘Non-risk NAFLD’ groups were comparable with respect to age, gender 
and BMI (Table 2). LFAT content was similar in all three groups (Table 2; Fig. 3, bottom panel on 
the left). Serum total TAGs were significantly lower in the ‘TM6SF2 NAFLD’ and ‘PNPLA3 
NAFLD’ groups than in the ‘Non-risk NAFLD’ group (Table 2; Fig. 3, bottom panel on the right).  
Other lipid concentrations were comparable between the groups.  
 
We compared TAG concentrations measured by UPLC-MS between the ‘TM6SF2 NAFLD’ and the 
‘Non-risk NAFLD’ groups. The differences in circulating TAGs between the ‘TM6SF2 NAFLD’ 
and  ‘Non-risk NAFLD’ resembled those observed between the ‘PNPLA3 NAFLD’ and  ‘Non-risk 
NAFLD’ groups (Fig. 3, upper panel on right; Fig. 4). The differences in circulating TAGs between 
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the ‘TM6SF2EK/KK NAFLD’ and the ‘Non-risk NAFLD’ groups were largely confined to the most 
abundant TAG species i.e. TAG(16:0/18:2/18:1) and TAG(16:0/18:1/18:1) (Fig. 4 and 
Supplementary Fig. 1). These molecular species were also significantly deficient in the ‘PNPLA3 
NAFLD’ as compared to the ‘Non-risk NAFLD’ group (Figs. 3 and 4). 
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Discussion 
The present study replicates the association between the TM6SF2 variant encoding E167K and 
increased LFAT content. We extend previous data by examining how the variant (and increased 
liver fat) influences the circulating TAG profile and directly measured insulin sensitivity. We also 
analyzed how the TM6SF2 variant allele per se, when associated with NAFLD, influences 
circulating TAGs by comparing lipidomics profiles between three groups with NAFLD and similar 
amount of LFAT. These were NAFLDs associated with the TM6SF2 E167K but not the PNPLA3 
I148M variant allele (‘TM6SF2 NAFLD’), NAFLD associated with the PNPLA3 but not the 
TM6SF2 E167K (‘PNPLA3 NAFLD’) and NAFLD associated with neither (‘Non-risk NAFLD’). 
We found the TM6SF2 variant to be metabolically ’silent’ as individuals carrying this variant were 
characterized by preserved insulin sensitivity of lipolysis and hepatic glucose production despite 
having a clearly increased liver fat content. Comparison of NAFLD subgroups defined by genetic 
background of NAFLD revealed lower levels of major circulating TAGs in both ‘TM6SF2 
NAFLD’ and ‘PNPLA3 NAFLD’ compared to the ‘Non-risk NAFLD’ group.  
 
In the present study, the allele frequency of the TM6SF2 E167K variant was 7.2%. This frequency 
is identical to that reported in the Dallas Heart study (7.2% in European Americans) [3]. Consistent 
with the latter study in European Americans, mean liver fat content measured by the same 1H-MRS 
technique was 34% increased in carriers of the E167K minor allele in the present study. 
 
As in the Dallas Heart Study in the European American subjects (n=882), we found no significant 
differences in serum total TAG, HDL and LDL cholesterol concentrations between TM6SF2 variant 
allele carriers and non-carriers. Similarly, in a very recent study in 5643 Norwegians, the TM6SF2 
variant was associated with slightly lower total cholesterol but with no change in total TAG or HDL 
cholesterol concentrations [14]. However, in larger cohorts in which lipid concentrations but not 
LFAT content have been measured, serum TAGs and LDL cholesterol concentrations have been 
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significantly lower in carriers of the E167K allele as compared to non-carriers [3]. In mice, 
selective knockdown of TM6SF2 in the liver by short hairpin RNAs decreased protein levels of 
TM6SF2 and total TAG and cholesterol concentrations in the study of Kozlitina et al. [3], while 
Holmen et al. found a significant decrease in cholesterol but not TAGs [14]. There is thus some 
variation in the association between the gene variant and changes in serum lipids as well as 
differences in the lipoprotein changes associated with TM6SF2 deficiency between mouse models 
and between mouse and man. However, it is clear that the TM6SF2 E167K allele is not associated 
with the hypertriglyceridemia typically characterizing subjects with NAFLD [2]. 
 
In the present study, comparison of the circulating TAG profiles between ‘TM6SF2 NAFLD’ and 
‘Non-risk NAFLD’ showed that major circulating TAG species i.e. TAG(16:0/18:2/18:1) and 
TAG(16:0/18:1/18:1) were decreased. We have previously shown by analyzing human liver 
biopsies [15] and by direct measurement of TAG fluxes across the splanchnic bed  [16]  that these 
TAGs are increased once the liver is fatty and are also the main constituents of VLDL [17]. Thus, 
plasma is lacking TAGs, which are overrepresented in the fatty liver and in VLDL. These data are 
consistent with those in mice, in which silencing of TM6SF2 decreases VLDL TAG production [3]. 
 
Regarding the lower levels of TAGs in ‘PNPLA3 NAFLD’ as compared to ‘Non-risk NAFLD’, we 
have previously shown [4] that absolute and relative deficiency of monounsaturated TAGs 
characterizes I148M variant allele carriers. Such data are in keeping with those in mice showing 
that overexpression of the human I148M variant enriches these TAGs in the liver [18]. In the 
present study, the TAG profiles of both ‘TM6SF2 NAFLD’ and ‘PNPLA3 NAFLD’ were 
characterized by decreases in common TAGs containing 52 carbons and two to four double bonds 
(Fig. 3 and Fig. 4). This could be a consequence of a decreased rate of secretion of these TAGs in 
VLDL [3, 19]. Thus, although the PNPLA3 and TM6SF2 gene variants influence intrahepatic TAG 
handling by different mechanisms, both variants are associated with lower levels of these TAGs in 
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the circulation. 
 
Compared to the ‘Non-risk NAFLD’ group, the ‘PNPLA3 NAFLD’ group had lower levels of 
saturated and monounsaturated TAG species than the ‘TM6SF2 NAFLD’ group (Fig. 3). Whether 
this difference was due to the much lower frequency of TM6SF2 than PNPLA3 variant allele 
carriers or to differences in the function of these two proteins is unclear. Since aging, male gender 
and obesity are each associated with an increased prevalence of NAFLD [2], one would have 
expected that individuals without the alleles would have differed in these respects from the groups 
carrying one of the variants. Interestingly no differences in age, gender or obesity were observed. 
Lack of differences in the phenotypic characteristics could be due to relatively small sample size or 
perhaps duration of obesity/NAFLD differed between the groups. On the other hand, serum TAG 
profiles did differ significantly and thus lack of phenotypic differences allowed comparison of 
circulating TAGs independent of age, gender and obesity.  
 
Our study is the first to directly compare insulin sensitivity between TM6SF2EK/KK and TM6SF2EE 
carriers. We found that the intercepts relating liver fat and hepatic insulin sensitivity of glucose 
production as well as lipolysis differed significantly between the genotypes. Thus, for any given 
liver fat content, hepatic and peripheral insulin sensitivity were higher in TM6SF2EK/KK as compared 
to TM6SF2EE carriers (Fig. 2).  Expressed in another way, liver fat content was significantly higher 
in TM6SF2EK/KK as compared to TM6SF2EE carriers for any given degree of insulin sensitivity. 
These data are consistent with the lack of a difference in fasting insulin concentrations in the face of 
different liver fat contents in the Dallas Heart Study [3]. The greater suppression of lipolysis by 
insulin in the TM6SF2EK/KK than the TM6SF2EE carriers implies that increased FFA delivery does 
not contribute to increased liver fat content or VLDL TAG synthesis. Although many studies have 
reported a positive correlation between liver fat and hepatic insulin resistance in humans [2], many 
murine models accumulate liver fat without accompanying insulin resistance [20]. Previous small 
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studies in humans with mutations or genetic variations in genes such as ATGL and CGI58, which 
cause fat accumulation in the liver but not insulin resistance, support the idea that liver TAG is not 
sufficient to cause insulin resistance or its consequences such as hypertriglyceridemia and 
dysglycemia [20].  
 
A couple of limitations of the present study should be recognized when interpreting the results.  The 
sample size, albeit large considering the number of lipidomic analyzes was small and therefore the 
observed differences may underestimate true differences between the groups. The subjects were 
normal-weight or overweight/obese volunteers participating in various metabolic studies who 
agreed to have their DNA analyzed and therefore do not represent a population-based random 
sample. For example, the higher liver fat content in the present study in both TM6SF2EK/KK and the 
TM6SF2EE  carriers (median 11.2 vs. 6.5%) compared to the European Americans in the population-
based Dallas Heart Study (4.9 vs. 3.5%) could have been due a higher BMI in the present study (33 
kg/m2) than the Dallas Heart Study cohort (∼29 kg/m2) [3]. 
 
After submission of this manuscript, Liu et al. reported that the TM6SF2 variant encoding E167K is 
associated with hepatic fibrosis/cirrhosis, independent of age, BMI, type 2 diabetes mellitus and 
PNPLA3 rs738409 genotype [21]. The association of the TM6SF2 variant with steatosis was 
marginally significant. We found the amount of liver fat to be clearly dependent on the TM6SF2 
genotype, perhaps because use of 1H-MRS enables measurement of liver fat in a larger volume than 
when using a liver biopsy. Our data do not exclude the possibility that the gene variant is associated 
with fibrosis since liver biopsies were not obtained.   
 
We conclude that the NAFLD associated with the TM6SF2 variant encoding E167K is 
metabolically silent. It increases liver fat content but this is not accompanied by decrease in whole 
body or hepatic or adipose tissue insulin sensitivity. It is associated with decreases of circulating 
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total TAGs and those that are enriched in the liver and VLDL of subjects with ‘Non-risk NAFLD’. 
Lack of these metabolic sequelae could decrease the risk from type 2 diabetes and cardiovascular 
disease in these NAFLD subjects. Genotyping to identify carriers of the PNPLA3 and TM6SF2 
variants might thus help in identification of subjects who are at risk of developing advanced liver 
disease but not the metabolic problems associated with ‘Non-risk NAFLD’. 
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Table 1. Characteristics of the study subjects according to the TM6SF2 E167K genotype.  
 
Characteristic 
TM6SF2EK/KK 
(n=41) 
TM6SF2EE 
(n=259) 
p-value 
Age (years) 50±2 47±1 NS 
Gender (% women) 39 37 NS 
Type 2 Diabetes (%) 24 28 NS 
BMI (kg/m2) 32.5±1.0 33.7±0.5 NS 
fP-Glucose (mmol/l) 6.0 (5.4-7.5) 5.9 (5.4-7.0) NS 
fS-Insulin (mU/l) 10.0 (7.0-16.6) 11.0 (6.5-15.8) NS 
HOMA-IR 2.9 (1.8-4.9) 3.0 (1.7-4.9) NS 
HbA1C (%) 5.8 (5.5-6.6) 5.8 (5.5-6.3) NS 
Systolic BP (mmHg) 133±2 133±1 NS 
Diastolic BP (mmHg) 84±1 83±1 NS 
fS-Triglycerides (mmol/l) 1.40 (1.00-1.75) 1.48 (1.06-2.11) NS 
fS-HDL cholesterol (mmol/l) 1.29 (1.11-1.61) 1.21 (1.04-1.53) NS 
fS-LDL cholesterol (mmol/l) 2.91 (2.37-3.50) 2.88 (2.25-3.50) NS 
FFA (µmol/l) 628 (464-812) 635 (495-809) NS 
S-AST (IU/l) 30 (24-37) 29 (23-44) NS 
S-ALT (IU/l) 34 (23-47) 34 (23-55) NS 
S-ALP (IU/L) 73 (64-136) 78 (64-105) NS 
S-GGT (U/l) 35 (19-55) 35 (20-63) NS 
PNPLA3 (PNPLA3II/PNPLA3IM/MM) (n) 19/22 130/129 NS 
Data are in n (%), means ± SEM or median (25th-75th percentile), as appropriate. 
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Table 2. Characteristics of the three NAFLD groups. This comparison includes all subjects 
with NAFLD (liver fat ≥  5.56%) (n=154). 
 
Total 
TM6SF2 NAFLD 
(n=13) 
PNPLA3 NAFLD 
(n=77) 
Non-risk NAFLD 
(n=64) 
Age (years) 49.5±13.3 47.5±11.2 47.6±10.7 
Gender (% women) 46 51 53 
Type 2 Diabetes (%) 38 45 33 
BMI (kg/m2) 32.6±6.1 35.7±7.8 33.5±5.8 
fP-Glucose (mmol/l) 6.2 (5.6-10.7) 6.2 (5.7-7.7) 6.6 (5.7-8.0) 
fS-Insulin (mU/l) 14.2 (10.4-19.0) 14.0 (9.0-19.2) 13.6 (10.6-19.7) 
HOMA-IR 3.8 (2.8-5.4) 3.7 (2.5-5.4) 4.5 (2.8-6.1) 
HbA1C (%) 6.0 (5.6-7.4) 6.0 (5.6-6.9) 6.0 (5.7-7.7) 
Systolic BP (mmHg) 135±18 135±16 134±15 
Diastolic BP (mmHg) 86±11 85±9 83±9 
fS-Triglycerides (mmol/l) 1.41 (1.06-1.97)* 1.60 (1.22-2.17)*† 1.92 (1.42-2.75) 
fS-HDL cholesterol (mmol/l) 1.29 (1.13-1.42) 1.12 (1.00-1.34) 1.14 (0.94-1.27) 
fS-LDL cholesterol (mmol/l) 2.87 (2.07-3.48) 2.82 (2.23-3.46) 3.20 (2.57-3.73) 
fS-FFA (µmol/l) 625 (486-722) 628 (541-808) 718 (583-823) 
S-AST (IU/l) 33 (27-43) 39 (30-53)*† 31 (24-43) 
S-ALT (IU/l) 42 (33-52) 51 (34-88)*† 38 (28-62) 
S-ALP (IU/L) 79 (55-126) 71 (65-93) 83 (64-132) 
S-GGT (U/l) 46 (25-78) 48 (32-66) 34 (24-77) 
LFAT (%) 15.8 (11.2-23.3) 15.6 (9.8-21.0) 11.9 (8.2-20.5) 
NASH score# -1.80 (-1.92--1.41) -0.88 (-1.31-0.03) -1.70 (-2.00--1.47) 
 25 
Data are in n (%), means ± SEM or median (25th-75th percentile). † p < 0.05 for one-way ANOVA; * 
p < 0.05 for LSD post hoc test compared with the ‘Non-NAFLD risk’. #: ‘NASH score’ estimated 
based on AST, PNPLA3 genotype and fS-insulin [12]. 
 
FIGURE LEGENDS  
Fig. 1.  Liver fat (%) measured by 1H-MRS (panel on the left) and distribution of triglyceride 
species in plasma (panel on the right) in carriers of the E167K variant in TM6SF2 (TM6SF2EK/KK) 
and non-carriers (TM6SF2EE). Liver fat and concentrations of plasma TAGs are shown in mean ± 
SEM (*p < 0.05). 
 
Fig. 2.  Relationships between liver fat and hepatic (top panel) and adipose tissue insulin sensitivity 
(bottom panel) in TM6SF2EK/KK (closed circles) and TM6SF2EE (open circles) groups. There were 
no differences between the slopes of these regression lines between the two groups. The intercept of 
the regression line relating liver fat and insulin sensitivity of hepatic glucose production was 
significantly (p = 0.002) lower in the TM6SF2EK/KK than the TM6SF2EE group. Similarly, the 
intercept of the regression line relating liver fat and insulin sensitivity of lipolysis was significantly 
(p = 0.012) lower in the TM6SF2EK/KK than the TM6SF2EE group. These data show that for any 
given liver fat content, the abilities of insulin to suppress hepatic glucose production and inhibit 
lipolysis were significantly better in the TM6SF2EK/KK than the TM6SF2EE group.  
 
Fig. 3.  Comparison of concentrations of plasma TAGs between the ‘TM6SF2 NAFLD’ and ‘Non-
risk NAFLD’ (upper panel on the left) and between ‘PNPLA3 NAFLD’ and ‘Non-risk NAFLD’ 
(upper panel on right) groups. Liver fat was comparable between the three groups (bottom panel on 
the left), while serum total TAGs were significantly lower in the ‘TM6SF2 NAFLD’ and the 
‘PNPLA3 NAFLD’ as compared to the ‘Non-risk NAFLD’ group (bottom panel on the right). The 
color code denotes the log of the ratio between means of the groups for an individual TAG. The y-
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axes denote the number of carbons, and the x-axes the number of double bonds. The darker the blue 
color, the greater the decrease in the ‘TM6SF2 NAFLD’ as compared to the ‘Non-risk NAFLD’ 
group (upper panel on the left) or between the ‘PNPLA3 NAFLD’ as compared to the ‘Non-risk 
NAFLD’ group (upper panel on the right). The significant differences in individual TAGs are 
indicated (*p < 0.05, **p < 0.01).  
 
Fig. 4.  Distribution of differences in plasma TAG species between ‘TM6SF2 NAFLD’, PNPLA3 
NAFLD’ and ‘Non-risk NAFLD’ groups. X-axis indicates mean differences of absolute TAG 
concentrations between the ‘TM6SF2 NAFLD’ (panel on the left), PNPLA3 NAFLD’ (panel on the 
right) and ‘Non-risk NAFLD’ groups (*p < 0.05, **p < 0.01).    
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